Rottach, Anja-Martina
Ahrend, Hannes
Martin, Benedikt
Walther, Reinhard
Zimmermann, Uwe
Burchardt, Martin
Stope, Matthias B. http://orcid.org/0000-0003-4129-8854
Funding for this research was provided by:
Sanofi-Aventis Deutschland GmbH
Article History
Received: 6 November 2018
Accepted: 20 December 2018
First Online: 2 January 2019
Compliance with ethical standards
:
: By way of disclosure of conflict of interest, the compound cabazitaxel was kindly provided by Sanofi-Aventis Deutschland GmbH (Frankfurt/Main, Germany). The preparation of the manuscript for the present publication was financially supported by the company Sanofi-Aventis Deutschland GmbH. Sanofi-Aventis Deutschland GmbH has no influence on the published content. The authors alone are responsible for the scientific content of this publication.
: The manuscript does not contain clinical studies or patient data.